Standard BioTools Future Growth
Future criteria checks 2/6
Standard BioTools is forecast to grow earnings and revenue by 64% and 21.1% per annum respectively. EPS is expected to grow by 87% per annum. Return on equity is forecast to be -9.8% in 3 years.
Key information
64.0%
Earnings growth rate
87.0%
EPS growth rate
Life Sciences earnings growth | 17.0% |
Revenue growth rate | 21.1% |
Future return on equity | -9.8% |
Analyst coverage | Low |
Last updated | 09 May 2024 |
Recent future growth updates
Recent updates
Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?
Apr 09Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)
Mar 06Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable
Feb 17Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?
Jan 12Is Standard BioTools (NASDAQ:LAB) A Risky Investment?
Aug 13Fluidigm Corporation: Investment Opportunity
Jan 26Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?
Dec 15Is Fluidigm (NASDAQ:FLDM) A Risky Investment?
Jul 27Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point
Jun 20Fluidigm gains after report that activist takes 11% stake, may push for unit sale
May 11Fluidigm Corporation 2021 Q1 - Results - Earnings Call Presentation
May 07Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 278 | 9 | 9 | 15 | 3 |
12/31/2025 | 232 | -64 | -60 | -57 | 3 |
12/31/2024 | 201 | -153 | -114 | -116 | 3 |
3/31/2024 | 127 | -136 | -100 | -97 | N/A |
12/31/2023 | 106 | -75 | -46 | -43 | N/A |
9/30/2023 | 105 | -76 | -52 | -48 | N/A |
6/30/2023 | 105 | -84 | -65 | -62 | N/A |
3/31/2023 | 97 | -131 | -86 | -82 | N/A |
12/31/2022 | 98 | -190 | -93 | -89 | N/A |
9/30/2022 | 109 | -179 | -81 | -77 | N/A |
6/30/2022 | 112 | -163 | -66 | -62 | N/A |
3/31/2022 | 124 | -117 | -54 | -47 | N/A |
12/31/2021 | 131 | -59 | -57 | -44 | N/A |
9/30/2021 | 137 | -68 | -64 | -41 | N/A |
6/30/2021 | 148 | -60 | -58 | -36 | N/A |
3/31/2021 | 143 | -56 | -43 | -24 | N/A |
12/31/2020 | 138 | -53 | -28 | -15 | N/A |
9/30/2020 | 126 | -48 | -20 | -17 | N/A |
6/30/2020 | 113 | -55 | -21 | -17 | N/A |
3/31/2020 | 115 | -55 | -23 | -19 | N/A |
12/31/2019 | 117 | -65 | -38 | -35 | N/A |
9/30/2019 | 117 | -67 | -32 | -30 | N/A |
6/30/2019 | 120 | -69 | -31 | -30 | N/A |
3/31/2019 | 118 | -71 | -30 | -29 | N/A |
12/31/2018 | 113 | -59 | -26 | -25 | N/A |
9/30/2018 | 108 | -55 | -24 | -24 | N/A |
6/30/2018 | 104 | -56 | -29 | -28 | N/A |
3/31/2018 | 102 | -57 | -33 | -32 | N/A |
12/31/2017 | 102 | -61 | N/A | -24 | N/A |
9/30/2017 | 99 | -68 | N/A | -35 | N/A |
6/30/2017 | 97 | -72 | N/A | -41 | N/A |
3/31/2017 | 101 | -73 | N/A | -40 | N/A |
12/31/2016 | 104 | -76 | N/A | -39 | N/A |
9/30/2016 | 110 | -71 | N/A | -33 | N/A |
6/30/2016 | 117 | -61 | N/A | -32 | N/A |
3/31/2016 | 117 | -57 | N/A | -33 | N/A |
12/31/2015 | 115 | -53 | N/A | -35 | N/A |
9/30/2015 | 117 | -51 | N/A | -34 | N/A |
6/30/2015 | 118 | -56 | N/A | -30 | N/A |
3/31/2015 | 117 | -53 | N/A | -22 | N/A |
12/31/2014 | 116 | -53 | N/A | -23 | N/A |
9/30/2014 | 104 | -47 | N/A | -16 | N/A |
6/30/2014 | 92 | -37 | N/A | -8 | N/A |
3/31/2014 | 82 | -28 | N/A | -11 | N/A |
12/31/2013 | 71 | -17 | N/A | -2 | N/A |
9/30/2013 | 66 | -15 | N/A | -8 | N/A |
6/30/2013 | 60 | -15 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LAB's revenue (21.1% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: LAB's revenue (21.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LAB is forecast to be unprofitable in 3 years.